PEMF for Bone Fracture
Healing & Non-Union.

June 2026 · 9 min read · Bone Healing Protocol

The Bone Fracture Healing Problem

Approximately 5–10% of all fractures fail to heal adequately — classified as delayed unions (healing significantly slower than expected) or non-unions (failure to heal after 9 months with no progression). Non-unions are particularly costly: the standard treatment pathway involves repeat surgery, bone grafting, and prolonged immobilization, with revision procedures costing ₱300,000–₱800,000 and carrying significant morbidity.

Risk factors for impaired fracture healing — smoking, diabetes, osteoporosis, corticosteroid use, nutritional deficiency, and vascular disease — are all highly prevalent in the Philippines. This creates a large cohort of fracture patients who heal slowly and incompletely with standard orthopedic care alone. PEMF represents the only non-invasive, FDA-cleared modality with a 40-year evidence base for directly stimulating bone repair at the cellular level.

How PEMF Stimulates Bone Healing

Bone is a piezoelectric tissue — it generates electrical signals in response to mechanical stress, and these signals regulate osteoblast (bone-building) and osteoclast (bone-remodeling) activity. After a fracture, disruption of this electrical signaling environment is one of the key reasons healing slows or stalls. PEMF recreates and amplifies the electrical cues that govern bone repair:

1. Osteoblast proliferation and differentiation — PEMF upregulates Runx2 and BMP-2 transcription factors, directing mesenchymal stem cells toward osteogenic differentiation rather than fibrogenic pathways.
2. Calcium influx regulation — electromagnetic induction enhances calcium uptake via voltage-gated channels in osteoblasts, accelerating mineralization of the fracture callus.
3. Reduction of inflammatory cytokines at the fracture site — PEMF suppresses IL-1β and TNF-α, which inhibit osteogenesis when chronically elevated, allowing the repair cascade to progress.
4. Angiogenesis at the fracture gap — PEMF upregulates VEGF, promoting new blood vessel ingrowth that supplies the metabolically demanding bone repair process.
5. Fibrous tissue suppression — histological analysis confirms that PEMF-treated fractures show significantly less fibrous tissue at the fracture gap and more cartilaginous callus (the precursor to lamellar bone) than untreated controls.

The Evidence Base: Meta-Analysis of 14 RCTs

A systematic review and meta-analysis (PMID 32495506) of 14 randomized controlled trials encompassing 1,131 participants established the quantitative evidence base for PEMF in fracture healing:

• PEMF fracture healing rate: 79.7% (443 of 556 PEMF patients achieved union)
• Control fracture healing rate: 64.3% (370 of 575 control patients achieved union)
• Risk ratio: RR = 1.22 (95% CI = 1.10–1.35) — a 22% relative increase in healing rate
• Pain reduction: SMD = −0.49 (95% CI = −0.88 to −0.10)
• Healing time acceleration: SMD = −1.01 (95% CI = −2.01 to −0.00)
• Evidence quality: moderate, consistent across studies with low heterogeneity

Large-Scale Real-World Data: 1,382 Patients

A follow-up observational study (PMC6209359) of 1,382 patients treated with PEMF stimulation in clinical practice — the largest single dataset for this indication — reported an overall success rate of 89.6%, consistent with the meta-analysis results and confirming that trial outcomes translate to real-world clinical settings.

Tibial Non-Union: Prospective Clinical Study

A prospective clinical study (PMC3441225) of 44 patients with tibial shaft delayed unions and non-unions — the highest-risk fracture category — treated with PEMF confirmed radiological union in 34 of 44 cases (77.3%), avoiding repeat surgery in three-quarters of patients who had already failed initial fixation.

Clinical Protocol

Fracture Healing Parameters

High-Risk Patient Subgroups — Additional Protocol Notes

• Diabetic patients: extend treatment course to 16–24 weeks; ensure HbA1c is actively managed concurrently
• Osteoporotic patients: combine with ongoing bisphosphonate or anti-RANKL therapy; do not substitute PEMF for pharmacological bone protection
• Smokers: strongly counsel cessation; smoking reduces PEMF effectiveness by ~30% through vasoconstriction and impaired osteoblast response
• Elderly patients (65+): protocol same as standard; efficacy is maintained — 1,382-patient observational data includes significant elderly subpopulation

PEMF vs. Other Non-Union Management Options

Contraindications

PEMF bone healing protocols are broadly safe, including in populations with metallic orthopedic hardware. Specific contraindications:

• Active implanted electronic device (pacemaker, defibrillator, spinal cord stimulator) in or near the treatment field — do not treat
• Active malignancy at the fracture site — pathological fractures through metastatic lesions or primary bone tumors require oncology clearance before PEMF
• Pregnancy — do not treat lumbar/pelvic fractures in pregnant patients
• Unstable fracture without adequate fixation — PEMF augments biological healing; it does not substitute for mechanical stabilization. Ensure adequate fixation before initiating PEMF

PEMF is safe over all standard orthopedic metallic hardware (titanium nails, stainless steel plates, cobalt-chrome implants). The electromagnetic field passes through metal without heating, displacement, or corrosion risk.

The Business Case: Orthopedic Referral Partnerships

Non-union fractures represent the highest single PEMF revenue opportunity in orthopedics. A patient referred with a 6-month tibial non-union will undergo a 24-week protocol of daily sessions — approximately 120 sessions at ₱1,500–₱2,500 each, generating ₱180,000–₱300,000 in revenue per patient. At a 89.6% success rate, the clinic avoids the patient needing to proceed to revision surgery — a compelling clinical and financial story for orthopedic surgeon partners.

Even in standard acute fracture acceleration (not non-union), a 12-week, 3×/week protocol generates ₱54,000–₱90,000 per patient. With 70+ Israeli clinics (population: 9M) — now expanding to the Philippines — this orthopedic application is a proven, recurring revenue model in a surgical ecosystem that generates a steady stream of post-fracture referrals.

Frequently Asked Questions

Is PEMF effective for all fracture types?

The strongest evidence is for long-bone fractures (tibia, femur, radius, humerus) — the most common sites in the meta-analysis. Evidence for vertebral compression fractures, rib fractures, and skull fractures is more limited. The mechanism (osteoblast activation, callus formation) is universal to all bone, so clinical application extends beyond the specifically studied sites.

Can PEMF work alongside a bone stimulator already prescribed by the surgeon?

Most surgeons prescribe either PEMF or ultrasound bone stimulators — not both simultaneously. If a patient already has a prescription bone stimulator device, coordinate with the orthopedic surgeon before adding clinic PEMF to the protocol. Some surgeons prefer to use clinic PEMF instead of home stimulators because compliance is guaranteed.

How does PEMF compare to low-intensity pulsed ultrasound (LIPUS) for non-union?

Both modalities have comparable healing rate evidence. The practical advantage of PEMF is penetration depth — PEMF fields reach 20–25 cm, allowing effective treatment of deep fractures (femoral shaft, tibial plateau) where LIPUS penetration is insufficient. PEMF also has the advantage of treating multiple fracture sites in one session if the applicator is appropriately positioned.

What is the FDA clearance status for PEMF bone healing?

PEMF devices for bone healing were among the first applications to receive FDA 510(k) clearance (1979) — making this one of the longest-established FDA-cleared non-invasive medical device indications in orthopedics. This regulatory history substantially simplifies the medical device approval pathway for Philippine clinic operators versus newer device categories.